Claims
- 1. A pharmaceutical composition in unit dosage form for use in the treatment of depression and fatigue comprising a pharmaceutically acceptable carrier and an antidepressant/anti-fatigue effective amount of a compound selected from the group consisting of [1,2,4]triazolo[4,3-a]quinoxaline-4-amine bases of the formula: ##STR3## and the pharmaceutically acceptable acid addition salts thereof, wherein X and X.sup.1 are each selected from the group consisting of hydrogen, fluorine, chlorine, bromine and methoxy;
- R.sub.1 is selected from the group consisting of hydrogen, lower alkyl, lower perfluoroalkyl and phenyl; and
- R.sub.2 and R.sub.3 are each selected from the group consisting of hydrogen, lower alkyl, phenylalkyl having up to three carbon atoms in the alkyl moiety and alkanoyl having from two to five carbon atoms, provided that at least one of X, X.sup.1 and R.sub.1 is always other than hydrogen or lower alkyl when each of R.sub.2 and R.sub.3 is hydrogen or lower alkyl; or
- R.sub.2 and R.sub.3, when taken together, complete a piperazino ring.
- 2. A pharmaceutical composition as claimed in claim 1 wherein X and X.sup.1 are each hydrogen, Rl is trifluoromethyl, and R.sub.2 and R.sub.3 are each hydrogen or lower alkyl.
- 3. A pharmaceutical composition as claimed in claim 1 wherein X and X.sup.1 are each hydrogen, R.sub.1 is lower alkyl and R.sub.3 is acetyl.
- 4. A pharmaceutical composition as claimed in claim 3 wherein R.sub.1 is ethyl and R.sub.2 is hydrogen.
- 5. A pharmaceutical composition as claimed in claim 3 wherein R.sub.1 and R.sub.2 are both ethyl.
- 6. A pharmaceutical composition as claimed in claim 3 wherein R.sub.1 is ethyl and R.sub.2 is acetyl.
- 7. A pharmaceutical composition as claimed in claim 1 wherein at least one of X and X.sup.1 is fluorine, R.sub.1 and R.sub.2 are each hydrogen and R is lower alkyl.
- 8. A pharmaceutical composition as claimed in claim 7 wherein X is fluorine at the 8-position of the molecule and R.sub.3 is isopropyl.
- 9. A pharmaceutical composition as claimed in claim 7 wherein X is fluorine at the 7-position of the molecule, X.sup.1 is fluorine at the 8-position of the molecule and R.sub.3 is isopropyl.
- 10. A pharmaceutical composition as claimed in claim 1 wherein at least one of X and X.sup.1 is chlorine, R.sub.1 is lower alkyl or trifluoromethyl, R.sub.2 is hydrogen and R.sub.3 is hydrogen lower alkyl or alkanoyl having two to five carbon atoms.
- 11. A pharmaceutical composition as claimed in claim 10 wherein X is hydrogen, X.sup.1 is chlorine at the 8-position of the molecule, R.sub.1 is ethyl and R.sub.3 is isopropyl.
- 12. A pharmaceutical composition as claimed in claim 10 wherein X is hydrogen, X.sup.1 is chlorine at the 8-position of the molecule, R.sub.1 is ethyl and R.sub.3 is propionyl.
- 13. A pharmaceutical composition as claimed in claim 10 wherein X is hydrogen, X.sup.1 is chlorine at the 8-position of the molecule, R.sub.1 is trifluoromethyl and R.sub.3 is hydrogen
- 14. A pharmaceutical composition as claimed in claim 10 wherein X is hydrogen, X.sup.1 is chlorine at the 8-position of the molecule, R.sub.1 is trifluoromethyl and R.sub.3 is acetyl.
- 15. A pharmaceutical composition as claimed in claim 10 wherein X is hydrogen, X.sup.1 is chlorine at the 8-position of the molecule, R.sub.1 is trifluoromethyl and R.sub.3 is isopropyl.
- 16. A pharmaceutical composition as claimed in claim 10 wherein X is hydrogen, X.sup.1 is chlorine at the 8-position of the molecule, R.sub.1 is ethyl and R.sub.3 is acetyl.
- 17. A pharmaceutical composition as claimed in claim 10 wherein X is chlorine at the 7-position of the molecule, X.sup.1 is chlorine at the 8-position of the molecule, R.sub.1 is ethyl and R.sub.3 is hydrogen.
- 18. A pharmaceutical composition as claimed in claim 1 wherein at least one of X and X.sup.1 is fluorine, R.sub.1 is trifluoromethyl, R.sub.2 is hydrogen and R.sub.3 is hydrogen, lower alkyl or alkanoyl having from two the five carbon atoms.
- 19. A pharmaceutical composition as claimed in claim 18 wherein X is hydrogen, X.sup.1 is fluorine at the 8-position of the molecule and R.sub.3 is hydrogen.
- 20. A pharmaceutical composition as claimed in claim 18 wherein X is hydrogen, X.sup.1 is fluorine at the 8-position of the molecule and R.sub.3 is isopropyl.
- 21. A pharmaceutical composition as claimed in claim 18 wherein X is hydrogen, X.sup.1 is fluorine at the 8-position of the molecule and R.sub.3 is acetyl.
- 22. A pharmaceutical composition in unit dosage form for use in the treatment of depression and fatigue comprising an antidepressant/anti-fatigue effective amount of a compound selected from the group consisting of [1,2,4]triazolo[4,3-a]quinoxaline-4-amine bases of the formula: ##STR4## and the pharmaceutically acceptable acid addition salts thereof, wherein R.sub.1 and R.sub.2 are each hydrogen and R.sub.3 is ethyl or isopropyl;
- R.sub.1 is hydrogen or methyl, and R.sub.2 and R.sub.3 are each ethyl;
- R.sub.1 is ethyl, R.sub.2 is hydrogen and R.sub.3 is hydrogen, methyl or ethyl; and
- R.sub.1 is ethyl, and R.sub.2 and R.sub.3 are each methyl or ethyl.
- 23. A pharmaceutical composition as claimed in claim 22 wherein R.sub.1 and R.sub.2 are each hydrogen and R.sub.3 is ethyl.
- 24. A pharmaceutical composition as claimed in claim 22 wherein R.sub.1 is ethyl, R.sub.2 is hydrogen and R.sub.3 is ethyl.
- 25. A pharmaceutical composition as claimed in claim 22 wherein R.sub.1, R.sub.2 and R.sub.3 are each ethyl.
CROSS REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of co-pending application Ser. No. 528,361, filed Sept. 2, 1983, now U.S. Pat. No. 4,495,187, which , in turn, is a continuation-in-part of co-pending application Ser. No. 434,789, filed Oct. 18, 1982 and now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3839569 |
Dreikorn et al. |
Oct 1974 |
|
4008322 |
Dreikorn et al. |
Feb 1977 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
2249350 |
Apr 1974 |
DEX |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
528361 |
Sep 1983 |
|
Parent |
434789 |
Oct 1982 |
|